In a study of over 284,000 patients, GLP-1 receptor agonists demonstrated cardiorenal benefits compared to DPP4 inhibitors even in adults aged 80 and older with type 2 diabetes.
284,417 patients analyzedGLP-1 RAs showed cardiorenal benefits vs DPP4i even in patients aged ≥80
What the researchers found
GLP-1 RAs demonstrated cardiorenal benefits over DPP4 inhibitors in patients aged ≥80 with T2DM, extending the evidence base to the very elderly population.
Why it matters
Elderly patients are typically excluded from clinical trials, leaving doctors guessing about drug benefits in the oldest patients. This massive study provides evidence that GLP-1 drugs work for octogenarians too.
How the study worked
Retrospective comparative effectiveness study using TriNetX US database with 284,417 patients; GLP-1 RA vs DPP4i comparison.
What this study cannot tell us
Retrospective database study cannot prove causation; elderly patients on GLP-1 drugs may differ from DPP4i users in unmeasured ways; tolerability and side effects in the very elderly need consideration.
How to read the evidence
Large retrospective database study — provides substantial real-world evidence but cannot replace randomized trial data in this population.
When this study was published
Published in 2026, filling an important evidence gap for GLP-1 drug use in the very elderly.
The bigger picture
As the population ages, evidence supporting use of modern diabetes drugs in the very elderly is critical. This study helps ensure the oldest patients aren't denied effective treatments due to lack of data.
Questions still open
- Do the cardiorenal benefits of GLP-1 drugs outweigh the GI side effect burden in frail elderly patients?
- Should GLP-1 drugs be preferred over DPP4 inhibitors in all elderly diabetic patients?
Common questions
Are GLP-1 drugs safe for people over 80?
Why weren't elderly patients included in original GLP-1 trials?
Read the original research
GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes.
Journal of the American Geriatrics Society, 74(1), 96-106
Citation
Chen, Jui-Cheng; Fang, Yu-Wei; Liu, Ya-Fang; Chen, Mon-Ting; Tsai, Ming-Hsien. (2026). GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes.. Journal of the American Geriatrics Society, 74(1), 96-106. https://doi.org/10.1111/jgs.70187